Trials / Completed
CompletedNCT01387464
Aqueous Humor Concentration of InSite Vision (ISV) 303 (Bromfenac in DuraSite) to Bromday Once Daily (QD) Prior to Cataract Surgery
A Double-Masked Clinical Study To Determine The Aqueous Humor Concentration Of Bromfenac Sodium In Subjects Administered Multiple Topical Ocular Doses Of ISV-303 Or Bromday™ Once Daily (QD) Prior To Cataract Surgery
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Sun Pharmaceutical Industries Limited · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the aqueous humor concentration of bromfenac sodium in subjects administered multiple topical ocular doses of ISV-303 or Bromday™ QD prior to routine cataract surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ISV-303 | 0.075% bromfenac in DuraSite dosed QD |
| DRUG | Bromday™ | 0.09% bromfenac dosed QD |
Timeline
- Start date
- 2011-07-01
- Primary completion
- 2011-08-01
- Completion
- 2011-08-01
- First posted
- 2011-07-04
- Last updated
- 2021-11-19
- Results posted
- 2016-06-02
Source: ClinicalTrials.gov record NCT01387464. Inclusion in this directory is not an endorsement.